Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Multiple Ascending Doses of AON-D21 in Healthy Men
NCT05343819Phase 1Completed
- Sponsor
- Aptarion Biotech
- Start
- Apr 2022
- Primary completion
- Nov 2022
- Modality
- Antisense DNA, RNA Aptamers, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in community acquired pneumonia (CAP) comparing AON-D21 with Placebo (2 arms). Primary endpoints: Number of participants with treatment-related adverse events at 27 days and Number of participants with treatment-emergent adverse events per dosing cohort at 27 days. Started Apr 2022; status: completed.
02
Drugs
AON-D21
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on NCT05343819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05343819.